Universal Health Services delivered an 8.3% year-over-year increase in revenue for Q2 2026, surpassing Wall Street’s revenue expectations. Management pointed to a rebound in both acute care and behavioral health volumes, supported by investments in expanding capacity and disciplined expense management. President and CEO Marc D. Miller highlighted the opening of new hospital beds and the Alan B. Miller Medical Center in Florida as bolstering demand response, and noted that professional and general liability reserves were increased during the quarter to reflect higher claim severity industry-wide. While acute care admissions and surgical volumes rebounded, CFO Steve G. Filton cautioned that same facility volume growth was slightly moderated to reflect observed trends, adding, “We are just trying to be practically reflective of our first half performance.”
Is now the time to buy UHS? Find out in our full research report (it’s free for active Edge members).
Universal Health Services (UHS) Q2 CY2026 Highlights:
- Revenue: $4.64 billion vs analyst estimates of $4.59 billion (8.3% year-on-year growth, 1.1% beat)
- Adjusted EPS: $5.98 vs analyst expectations of $6.01 (in line)
- Adjusted EBITDA: $684 million vs analyst estimates of $686.3 million (14.7% margin, in line)
- Adjusted EPS guidance for the full year is $22.97 at the midpoint, missing analyst estimates by 1.8%
- EBITDA guidance for the full year is $2.66 billion at the midpoint, below analyst estimates of $2.70 billion
- Operating Margin: 11.1%, in line with the same quarter last year
- Same-Store Sales rose 8.2% year on year (2% in the same quarter last year)
- Market Capitalization: $10.2 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Universal Health Services’s Q2 Earnings Call
-
Ann Hynes (Mizuho): asked about the drivers behind acute care volume moderation. CFO Steve G. Filton explained that shifts toward alternate care settings like ambulatory surgery centers are impacting volume growth but emphasized continued satisfaction with overall volume trends.
-
Andrew Mok (Barclays): questioned the drivers of expected EBITDA growth acceleration in the second half of the year. Filton highlighted the ramp-up of new bed additions, Cedar Hill hospital’s path to breakeven, and labor cost moderation as key factors.
-
Matthew Dale Gillmor (KeyBanc): asked about the future of the Florida DPP program and opportunities for other supplemental payments. Filton said future program impacts are uncertain and not included in current guidance, and that other state programs are unlikely to be material in the near term.
-
Jason Cassorla (Guggenheim Partners): inquired about behavioral health volume growth and the impact of headcount expansion. Filton noted that outpatient growth has been slower than anticipated, with the Talkspace acquisition expected to accelerate this area after integration.
-
AJ Rice (UBS): asked about the long-term impact of reductions in Medicaid supplemental payments under the One Big Beautiful Bill Act. Filton outlined steps to improve productivity, invest in technology, and focus on less Medicaid-dependent service lines to mitigate the impact.
Catalysts in Upcoming Quarters
In the quarters ahead, our team will monitor (1) the ramp-up of newly added hospital beds and the Alan B. Miller Medical Center’s performance, (2) the pace and success of integrating Talkspace and expanding virtual behavioral health offerings, and (3) progress on expense controls and managing liability reserve increases. The durability of supplemental Medicaid funding and evolving payer mix trends will also be critical indicators.
Universal Health Services currently trades at $168.50, up from $159.31 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
